Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
Autori: Marchetti, C.; Fagotti, A.; Fruscio, R.; Cassani, C.; Incorvaia, L.; Perri, M.T.; Sassu, C.M.; Camnasio, C.A.; Giudice, E.; Minucci, A.; Seca, M.; Arbustini, E.; Vertechy, L.; De Bonis, M.; Boccia, S.M.; Giannarelli, D.; Salutari, V.; Distefano, M.; Ferrandina, M.G.; Nero, C.; Musacchio, L.; Russo, A.; Scambia, G.; Lorusso, D.
